Funds › Davern Capital Partners, LP
Davern Capital Partners, LP
13F for Q3 2026, filed Nov 12, 2026. 17 positions worth $514.1M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Davern Capital Partners, LP in the latest 13F quarter?
Using 13F.ai, how has Davern Capital Partners, LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Davern Capital Partners, LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | BNTX BioNTech SE · ADR | 682,148 | $67.1M | 13.0% | -9.6% | 13F ↗ |
| 2 | RPRX Royalty Pharma plc | 974,412 | $56.9M | 11.1% | -15.7% | 13F ↗ |
| 3 | INSM Insmed Incorporated · Com Par $.01 | 496,047 | $56.6M | 11.0% | -11.4% | 13F ↗ |
| 4 | ROIV Roivant Sciences Ltd. | 1.47M | $53.9M | 10.5% | -23.8% | 13F ↗ |
| 5 | IONS Ionis Pharmaceuticals, Inc. | 1.09M | $48.5M | 9.4% | +36.1% | 13F ↗ |
| 6 | ARGX argenx SE · ADR | 37,597 | $36.1M | 7.0% | New | 13F ↗ |
| 7 | REGN Regeneron Pharmaceuticals, Inc. | 40,661 | $30.8M | 6.0% | -56.1% | 13F ↗ |
| 8 | NTRA Natera, Inc. | 63,200 | $26.1M | 5.1% | -46.9% | 13F ↗ |
| 9 | ABVX Abivax SA · ADR | 219,183 | $21.7M | 4.2% | New | 13F ↗ |
| 10 | VERA Vera Therapeutics, Inc. | 628,274 | $20.3M | 3.9% | +25.9% | 13F ↗ |
| 11 | MLYS Mineralys Therapeutics, Inc. | 695,152 | $17.5M | 3.4% | -19.1% | 13F ↗ |
| 12 | LEGN Legend Biotech Corporation · ADR | 828,880 | $16.5M | 3.2% | -30.4% | 13F ↗ |
| 13 | ARWR Arrowhead Pharmaceuticals, Inc. | 229,300 | $15.0M | 2.9% | New | 13F ↗ |
| 14 | LLY Eli Lilly and Company | 12,600 | $14.6M | 2.8% | New | 13F ↗ |
| 15 | GENB Generate Biomedicines, Inc. | 824,679 | $12.4M | 2.4% | Unchanged | 13F ↗ |
| 16 | VRDN Viridian Therapeutics, Inc. | 560,710 | $11.5M | 2.2% | New | 13F ↗ |
| 17 | AVTX Avalo Therapeutics, Inc. | 564,441 | $8.7M | 1.7% | +20.4% | 13F ↗ |
Changes since Q2 2026
5 new, 3 added to, 8 trimmed, 3 exited, 1 unchanged. By estimated dollars.
New positions (5)
Added to (3)
Trimmed (8)
| REGN Regeneron Pharmaceuticals, Inc. | 40,661 | -56.1% | -$39.4M |
| NTRA Natera, Inc. | 63,200 | -46.9% | -$23.1M |
| ROIV Roivant Sciences Ltd. | 1.47M | -23.8% | -$16.8M |
| RPRX Royalty Pharma plc | 974,412 | -15.7% | -$10.6M |
| INSM Insmed Incorporated · Com Par $.01 | 496,047 | -11.4% | -$7.3M |
| LEGN Legend Biotech Corporation · ADR | 828,880 | -30.4% | -$7.2M |
| BNTX BioNTech SE · ADR | 682,148 | -9.6% | -$7.1M |
| MLYS Mineralys Therapeutics, Inc. | 695,152 | -19.1% | -$4.1M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer